Celgene
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-486 (ONUREG®) in combination with venetoclax in relapsed and/or refractory Acute Myeloid Leukemia (AML) and newly diagnosed AML.
Leukemia, Myeloid, Acute
CC-486
Venetoclax
PHASE1
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 6 participants |
Masking : | NONE |
Primary Purpose : | TREATMENT |
Official Title : | A Phase 1B, Open-label, Global, Multicenter, Dose Determination Study to Evaluate Safety, Tolerability, and Preliminary Efficacy of CC-486 (ONUREG®) in Combination Therapy in Subjects With Acute Myeloid Leukemia (AML) |
Actual Study Start Date : | 2021-12-01 |
Estimated Primary Completion Date : | 2024-01-08 |
Estimated Study Completion Date : | 2024-01-08 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Local Institution - 104
Stanford, California, United States, 94305-5317
Not yet recruiting
Local Institution - 110
Denver, Colorado, United States, 80218
Not yet recruiting
Local Institution - 105
Boston, Massachusetts, United States, 02114
Not yet recruiting
Local Institution - 106
New York, New York, United States, 10029
Not yet recruiting
Local Institution - 113
New York, New York, United States, 10065
Not yet recruiting
Local Institution - 102
Cleveland, Ohio, United States, 44195
Not yet recruiting
Local Institution - 111
Oklahoma City, Oklahoma, United States, 73104
Not yet recruiting
Local Institution - 101
Houston, Texas, United States, 77003
Not yet recruiting
Local Institution - 202
North Melbourne, Victoria, Australia, 3002
Not yet recruiting
Local Institution - 201
Melbourne, Australia, 3004